The only deviation from the above protocol was the conduct of additional analyses to estimate the number of breast cancer deaths that could have been prevented in Brazil, in 2012 (Text S3):
. Appendix S1_Study Protocol
Breast cancer stage at diagnosis in Brazil Background
Breast cancer incidence in Brazil, as in most low/middle-income countries (LMICs), has been increasing in recent years, reflecting population aging as well as adoption of riskier reproductive and lifestyle behaviours. Albeit incidence is still considerably lower than in high income countries (HICS), mortality from the disease is as high as in many HICs (14·3/100,000 in Brazil vs. 14·9/100,000 in the US and 12·5/100,000 in Norway). 1 Breast cancer is a potentially curable disease if diagnosed at an early stage. Advanced stage at diagnosis is more difficult and costly to treat, and is associated with increased morbidity and poor survival in HICs, and Brazil. Thus, a potential reason for the disproportionately high breast cancer mortality in Brazil is late-stage at diagnosis.
A shift towards diagnosing breast cancer at an early stage is a necessary, albeit not sufficient, prerequisite for reducing mortality from the disease. This can be achieved through downstaging (also known as stage migration), i.e. by ensuring that symptomatic women are diagnosed and treated at an early stage, or through screening to detect asymptomatic disease. Early detection control policies in Brazil, as in many other LMICs, have tried to emulate those being currently implemented in HICs by focusing mainly on the latter with the Ministry of Health recommending, since 2004, biannual mammography for all women aged 50-69 years. However, it is unclear whether they have led to reductions in late-stage disease at diagnosis. Promotion of breast cancer awareness and yearly clinical breast examinations for women aged ≥40 years were also recommended but received less attention.
Study aims
The specific aims of the study are to:
-Estimate the prevalence of late-stage breast cancer at diagnosis, overall and across the various ethnoracial and social strata in the country during the period 2001-2014; -Investigate the extent to which prevalence of late-stage disease was affected by the early detection control policies introduced in 2004; -Compare the prevalence of late-stage in Brazil with long-term data from high-income countries stretching back to the period prior to the introduction of mammographic screening in these settings; and -Consider the implications of the findings for cancer control policies in Brazil and other LMICs facing an increasing breast cancer burden.
Data sources
The Brazilian unified health system (Sistema Único de Saúde, SUS) was established by the government in 1988 to provide universal free access to health care. A network of SUS-affiliated hospital-based cancer registries (RHC) was set up in the 1990s, and an electronic platform for standardised collection of data on each patient's sociodemographic characteristics, tumour features and health care access (sisRHC), including the variables listed in Table 1 , was adopted in 2000. 2 The RHC network comprises two different sources: the Integrator Module of RHCs (ttps://irhc.inca.gov.br/RHCNet/) coordinated by the Brazilian National Cancer Institute, and the RHC of São Paulo state (www.fosp.saude.sp.gov.br) coordinated by Fundação Oncocentro of São Paulo (FOSP). They use similar procedures except that the latter does not collect data on self-reported ethnicity/race, marital status, main basis for diagnosis, and centre where patient was first seen. Together they comprise health care providers (HCP) with oncological accreditation located in each of the 26 Brazilian states and the Federal District. The sisRHC data are publically available on ttps://irhc.inca.gov.br/RHCNet/. Although there are over 20 local population-based cancer registries in Brazil, covering mainly urban populations, none of them collects data on tumour stage at diagnosis.
Anonymised individual-level records will be extracted from the sisRHC database for all women with a breast cancer diagnosis. The study will comply with the RECORD statement.
To compare trends in the prevalence of late-stage breast cancer in Brazil, overall and in different ethnoracial and social strata, with those in high-income countries we will search for published long-term data, stretching back to the time period prior to the introduction of screening in these settings, from population-based cancer registries which have collected such historical data.
Study design
Case-only analysis of individual-level record data from the sisRHC database.
Study population
Women in the sisRHC database will be eligible if:
-they were diagnosed with an invasive breast cancer (ICD-10:C50
3 ) in a SUS-affiliated HCP during 2001-2014; -they were aged 18-89 years at the time of the diagnosis.
Women will be excluded if:
-year of breast cancer diagnosis is missing or outside the 2001-2014 range -age at diagnosis is missing or outside the 18-89 range -their diagnosis is a non-invasive breast cancer (TNM 4 behaviour codes: 3, 6, and 9) -their breast cancer was diagnosed in a health care provider (HCP) not affiliated with SUS, or if the affiliation of the HCP at the time of the diagnosis was unknown.
The selection process, including the number of women excluded by reason, will be provided in a detailed flowchart.
Outcome and exposures
The outcome variable of interest would be stage of breast cancer at diagnosis as defined by the Classification of Malignant Tumours (TNM). 4 The exposure variables will be classified as:
-Patient-related variables, i.e. ethnicity/race, educational level, marital status, migration out of region of birth, age at diagnosis, year at diagnosis, and region of residence at diagnosis.
-Tumour-related variables -main basis for diagnosis, histological type, and presence of multiple tumours in the breast(s)
-HPC-related -type of HCP, level SUS oncological accreditation, type of management, and type of service where that patient was first seen.
The patient-related variables will be the primary exposures of interest. Tumour-related and HCP-related variables will be taken as covariates in the analysis.
Statistical analysis
Comprehensive data checks will be performed to identify inconsistencies of the data, and data missingness patterns will be investigated.
The distribution of stage at diagnosis will be examined overall, and by patient-, tumour-, and HPC-related variables. Prevalence of late stage at diagnosis (TNM III and IV combined), overall and across ethnoracial and social strata, will be estimated and compared with similar international data.
Logistic regression models will be used to estimate odds ratios (ORs), with 95% confidence intervals (CIs), for late-stage (TNM III/IV) versus early stage (TNM I/II) breast cancer in relation to patient-related variables, before and after adjustment for covariates. Analyses will be conducted overall, and separately for each ethnoracial stratum.
To assess the robustness of the overall and stratum-specific results the analyses will be repeated on:
Multiple imputed data (MI) to address potential biases due to outcome and covariate data incompleteness. MI data will be generated using a fully conditional specification approach under the assumption of missingness at random (MAR). 5 For flexibility, the imputation model will include the main predictors of missingness, the outcome (stage), and all the variables contributing to the analysis models, including interactions between year of diagnosis and all other variables. To control the Monte Carlo error of estimates and standard errors, 50 or more imputation sets will be generated.
(ii)
Women aged 50-69 years at diagnosis, the age-group targeted by mammographic screening;
(iii) Women resident in the South, the region with the highest RHC coverage;
(iv) Using a more stringent definition of "incidence", i.e. restricted to women first diagnosed and treated in the HCP that submitted the data to RHC, to ensure that the recorded stage was actually ascertained at diagnosis. (c) Consider use of a flow diagram RECORD 13.1: Describe in detail the selection of the persons included in the study (i.e., study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.
Results, Study design and participants subsection. We assumed that the protective effect of mammographic screening carries over to the ages beyond 69 years, i.e. beyond the upper limit of the age-group targeted by screening.
Calculations
-Using the data from the table above, the total number of deaths in Brazil, in 2012, among women aged 50+ was 12,376.
-We considered two extreme scenarios: A. Mammographic screening had actually led to a 20% reduction in mortality from breast cancer in 2012 among women aged 50+ who had been screened, with this percentage corresponding to the effect estimated in a meta-analysis of randomized controlled trials with 100% coverage. 
II. Number of breast cancer deaths that could be prevented by downstaging
We aimed to estimate the number of breast cancer deaths that would have been prevented in Brazil, in 2012, if varying percentages of women diagnosed with stage III/IV breast cancer in the previous 5 years had been diagnosed at stage II instead of stage III/IV. To achieve this, we have used breast cancer mortality and incidence data, as well as estimated breast cancer survival rates and hazard ratios, which were obtained from different sources and then combined with data from our study.
Data
We used the following information: Figure 4 . From the figure we derived the stage III 1-year survival rates to be 92%. Assuming that the hazard rate for stage III, III derived above, applies to the most frequent age group (age 40-49), we calculated survival probabilities for all combinations of age and stage and for a selection of times, using the relationship between hazard rates and survival probabilities (also used above):
4)

Sstage,age (t)=exp(-stage,age *t),
where the derived values of stage,age =III*HRstage *HRage, the HRs are given above, and t=1,2,3,4,5. Given the coarser classification of younger women in the GLOBOCAN data, we assumed the 30-39 year HRs also to be valid for all 18-39 year olds.
For example, the derived 1-year stage-and age-specific survival probabilities are: Similar values were calculated for the 2-, 3-, 4-and 5-year survival probabilities.
(c) Calculation of the number of lives saved under different scenarios, in comparison with the status quo.
In this last step, we used the data above to predict the number of breast cancer deaths in 2012 and then consider alternative scenarios where some of the women who were stage III or IV at diagnosis are migrated to stage II.
We first predict the number of deaths in 2012 assuming: 
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We then calculated the number of breast cancer deaths in 2012 that could have been saved under different scenarios. The scenarios are:
Scenario 1: 100% of women with an initial stage III or IV at diagnosis were instead diagnosed as stage II.
Scenario 2: 80% of women with an initial stage III or IV at diagnosis were instead diagnosed as stage II.
Scenario 3: 50% of women with an initial stage III or IV at diagnosis were instead diagnosed as stage II.
In scenario 1, all women originally diagnosed at stage III/IV would have migrated to stage II. Hence, for these women the expected number of deaths was calculated using the survival rate of stage II women of the same age, instead of the survival rate of their given stage. For the other scenarios (1 to 3), the survival rate for stage II was reassigned only for, respectively, 80% and 50% of the original stage III/IV patients. CI: confidence interval; HCP: health care provider; OR: odds ratio; Phet: P for heterogeneity; Pt: P for linear trend a This represents the whole eligible study population with known stage which, by design, had no-missing data on year, age and region of residence at diagnosis (see Figure S1 ). Data on type of HCP management was also available for all these women. b Subset of eligible women with complete data on all the analysis covariates listed in Table 1 : year of diagnosis, age at diagnosis, region of residence at diagnosis, race/ethnicity, educational level, marital status, whether they had migrated out of the region of birth, the main basis for diagnosis, histological type, presence of multiple tumour, type of HCP, level of SUS (Sistema Único de Saúde) oncological accreditation, type of HCP management, and service where the patient was first seen. c Subset of eligible women with incomplete data on at least one of the variables listed in footnote b. d Records from São Paulo state were, by design, incomplete as its RHC used a different form which did not include collection of data on the following variables: ethnicity, marital status, main basis for breast cancer diagnosis, and centre where patient was first seen. Table 1 . Consequently, records from São Paulo state were excluded (see Methods section). c Based on self-reported race and skin colour classified according to the Brazilian Census (https://sidra.igge.gov.br/Tabela/3175). d Adjusted for age, year and region of residence at breast cancer diagnosis. e Adjusted for all patient-, tumour-and health care provider-related variables listed in Table 1 . f No. years of formal education -less than primary education: ≤ 4 years; primary education: 5-9 years; secondary education: 8-12 years; university: >12 years. g Each region is formed by smaller Unidade Federativas (UF). The UF of residence of the patient was the same as the UF where her HCP was located for all participants. Table 1 . Consequently, records from São Paulo state were excluded (see Methods section). b The region with the highest RHC coverage (see Methods section). c Subset of patients whose cancer was diagnosed for the first time in the HCP that submitted the data (a more stringent definition of incidence -see Methods section). d Adjusted for all patient-, tumour-and health care provider-related variables listed in Table 1 . e Based on self-reported race/skin colour classified according to the Brazilian Census (https://sidra.igge.gov.br/Tabela/3175) f No. years of formal education -less than primary education: ≤ 4 years; primary education: 5-9 years; secondary education: 8-12 years; university: >12 years. g Each region is formed by smaller Unidade Federativas (UF). The UF of residence of the patient was the same as the UF where her HCP was located for all participants.
Figure S1. Distribution of Age and Year of Diagnosis in Each Region by Record Completeness
Complete records are those with complete (non-missing) data on the outcome, the socio-demographic exposures and the potential confounding variables listed in Table 1 (1979-2013), Norway (1953-2013) and  the USA (1950-2013) 
